59 / 245
DOS Kongressen 2016 ·
59
Prognostic Factors for Survival of High Grade
Osteosarcoma - A 20 Year Single-institution
Assessment from Eastern Denmark
Thomas Colding-Rasmussen, Andrea Pohly Thorn, Peter Frederik Horstmann,
Michael Mørk Petersen
Musculoskeletal Tumor Section, Department of Orthopedic Surgery,
Rigshospitalet, University of Copenhagen, Denmark
Background:
Overall survival of patients diagnosed with high- grade osteosar-
coma (HO) – the most common primary bone cancer – has not improved sig-
nificantly the last 20 years. Accordingly, treating HO remains a major challenge.
Purpose / Aim of Study:
To evaluate prognostic factors for survival in patients
diagnosed with HO between 1990 and 2010 at the department of orthopedic
tumor surgery, Rigshospitalet, Copenhagen, Denmark (RH).
Materials and Methods:
156 patients received an osteosarcoma diagnosis in
the RH Pathologic database from 1990-2010. 101 patients (mean age=29
years, F/M ratio=56/45) were suited for further analysis. 55 patients were ex-
cluded due to either low grade classification (n=22), non-confirmed tentative
diagnosis (n=11), tumor in axial skeleton (n=18) or metastatic/relapsed tumor
(n=4). Statistics: Kaplan Meier survival analysis and Cox regression.
Findings / Results:
The probability of 5 – and 10 year survival from time of
diagnosis was 51% and 46% respectively. Metastatic disease (multivariate cox:
HR=3.5, CI 95%: 1.5-7.8) and tumor-size ≥10 cm (multivariate cox: HR: 2.9,
CI 95%: 1.5-5.4) at time of diagnosis, were statistically significant risk fac-
tors for decreased overall survival. Among patients treated with curative intent
(preoperative chemotherapy and surgery, n=79), the survival rate was higher
(multivariate cox: HR=2.8 CI 95%: 1.2-6.5), if the degree of tumor cell necrosis
was ≥90%.
Conclusions:
Overall survival for patients with HO in East Denmark is consist-
ent with the international average survival for this patient-group. Metastasis
and tumor- size ≥10 cm at time of diagnosis are significant prognostic factors
for surviving HO, as well as degree of chemotherapeutic induced tumor necrosis
among patients treated with curative intent.
No conflicts of interest reported
10.